In addition, high expression of ARSG, CD70, CTH, ERP29, FXN, NLE1, and PDK4 and low expression of BIRC3, ELL3, HIF1A, INHBA, MAEL, MEF2C, MMP9, PDK1, PRKCA, RARRES2, RRAGA, SNAP23, and UBQLN2 are associated with poorer outcomes in DLBCL patients. The gene discussed is NLE1; the disease is diffuse large B-cell lymphoma.